MetaCap

AngioDynamics (ANGO) vs BrainsWay (BWAY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BrainsWay (BWAY) has outperformed AngioDynamics (ANGO) over the past year, gaining 13.9% versus a loss of 9.5%. Over five years, BWAY leads with a +130.7% price change compared with -60.3% for ANGO. AngioDynamics is the larger company by market cap ($454.6 million vs $341.3 million), about 1.3 times the size, while BrainsWay is growing revenue faster (+29.0% vs +9.5%).

BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus -11.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANGO-9.54%BWAY+13.90%
+138%+56%-26%
Nov 21, 20251 yearNov 20, 2026
ANGO-62.10%BWAY+113.60%
+353%+125%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANGO versus BWAY key metrics
MetricANGOBWAY
Share price$10.81$8.48
Market cap$454.61M$341.35M
1-day change+0.46%-2.86%
YTD return-15.81%-10.83%
1-year return-9.54%+13.90%
5-year return-60.29%+130.75%
P/E ratio (TTM)—35.33
Forward P/E—16.96
EPS (TTM)$-0.78$0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$320.17M$41.02M
Revenue growth (YoY)+9.46%+29.04%
Net income (latest FY)$-36.74M$2.92M
Gross margin54.62%74.56%
Operating margin-12.47%3.39%
Net margin-11.48%7.12%
52-week high$16.29$17.40
52-week low$9.39$7.30
Distance from 52-week high-33.64%-51.26%
Analyst consensusnonestrong_buy
Avg. price target upside+82.70%+127.24%
Average volume651.16K110.35K
Shares outstanding42.05M40.25M
Employees632129
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BWAY has outperformed ANGO by 23.4 percentage points over the past year.
  • BrainsWay is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -11.5 cents for AngioDynamics.
  • BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs +9.46%).

About AngioDynamics

ANGO stock →

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.

Health Care · Medical/Dental Instruments · 632 employees

About BrainsWay

BWAY stock →

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 129 employees

ANGO vs BWAY FAQ

Which is bigger, AngioDynamics or BrainsWay?

AngioDynamics (ANGO) is larger, with a market capitalization of $454.61M compared with $341.35M for BrainsWay (BWAY).

Which stock has performed better over the past year, ANGO or BWAY?

BWAY returned +13.90% over the past 12 months, compared with -9.54% for ANGO (price return, excluding dividends). Past performance does not predict future results.

Are AngioDynamics and BrainsWay in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons